Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. - Wikidata - awgldk - TriplyDB

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

http://www.wikidata.org/entity/Q34296248

about

Functions of lncRNA HOTAIR in lung cancer Design of small molecule epigenetic modulators Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies EZH2 in Bladder Cancer, a Promising Therapeutic Target Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Functional and therapeutic significance of EZH2 in urological cancers EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.Small-molecular modulators of cancer-associated epigenetic mechanisms.Chromatin Memory in the Development of Human Cancers The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy Histone methylases as novel drug targets: developing inhibitors of EZH2.An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis.The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence.PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Targeting EZH2 for cancer therapy: progress and perspective.EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis.STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.Regulatory variation: an emerging vantage point for cancer biology.Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.The role of polycomb repressive complexes in biliary tract cancer.DNA Methylation and Colorectal Cancer Targeting of cancer stem cells by inhibitors of DNA and histone methylation.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma.Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment Expression and Dendritic Trafficking of BDNF-6 Splice Variant are Impaired in Knock-In Mice Carrying Human BDNF Val66Met Polymorphism.EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.

P2860

Q26849432-AE66E90F-3B1F-44F2-864D-A2361575E7F4 Q26850027-931CEB12-709F-4A28-812F-C46B0FC66920 Q28074716-570BC02A-F458-4587-AB49-EBC4D2FDA7BD Q28082054-11016802-4379-411C-A2E5-9A33979A3A25 Q28546856-8225214F-5105-4637-B0E7-A0181B654EEF Q33914244-5A0E9613-9719-4E18-A11C-4C0C55F7E2C3 Q33988909-A553495D-F8BC-4B67-B77C-1B240FB72AC8 Q34000385-C5C3ACE0-A4E2-4A33-840C-B03CEACBD8BF Q34310069-490B3963-B8AC-40FF-9A2E-E59934FC5A92 Q34401976-C867DB45-CF6A-4CBD-ABD9-8C788E79EEED Q34628002-7FD06204-2E0E-4129-A002-C3A0F55FADEA Q34979975-D9702F66-5D00-44C7-8C58-1579F4E303D2 Q35254822-D0A78642-2A13-49AE-80E0-3BCF875C63F5 Q35510392-24380C14-1B4B-4E96-B6D6-46192E92B7C9 Q35825840-B4329C6D-33D4-4FC7-B8EF-F8E093BA2EBF Q35949625-68850603-4EBA-4E77-B978-B0260509D747 Q36237945-934F4D74-62AE-45D5-A463-43711D531294 Q36427004-63658ACE-C597-47C6-9B0E-29C69165F629 Q36881958-D7123B7E-3E98-4497-A6B8-BC2AF999C771 Q37028708-A88E1005-7983-4D72-A5EA-1183830C293D Q37098331-EB81222B-374D-4DF8-B046-756D6E92BA97 Q37204063-58C8F4E0-2D88-4504-AF94-0651F316B244 Q37263917-3525E724-C3A6-4336-92E6-89F5806E612E Q37491122-CCD34A8A-8876-4261-96C5-6F6C9E4B5C6F Q38121136-5CBC8BFA-549B-4656-90E0-A1DD1FD3EEE1 Q38140920-17C7EBAB-833B-4BF6-9E75-DE85C81533DB Q38164307-6D34B90E-79BC-4BB8-98C5-0AA46DB1965C Q38185265-EF166A6F-3EC7-4DA1-8F93-F7E9DD61B8E8 Q38271374-AA6E9EED-7C9A-4334-9F87-C22DA46E5E38 Q38314840-B43657EA-9BEE-42A0-87A2-12EA5F571212 Q38500320-1160B73D-5678-4872-A4C6-7D65A194C887 Q38582589-2132D967-451D-497C-ABEC-C2F9D16436C1 Q38695240-0631B8C6-B71E-48F0-B97A-F243CBE1D9AC Q38832524-DC60CFF2-8070-4788-B685-01F55F72D4B6 Q38918235-12B3B40E-49C8-40B8-8C22-4EB861047FCC Q39009379-FB0C12ED-6CBE-4B37-9D4F-E20E14B84B14 Q39870818-D76130E3-8A80-4C01-BED2-E60E471135CB Q40014635-C0FDCA38-4CFD-4C07-9166-75EC2D6C34BF Q41999245-B83E10F9-CD3B-472F-B615-A1BBF6B469A3 Q42175070-6D4C8B39-EB03-413E-B93B-F52DB13BF03C

P2860

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

http://www.wikidata.org/entity/Q34296248

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@ast

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@en

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@nl

type

label

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@ast

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@en

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@nl

prefLabel

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@ast

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@en

Epigenetic therapy with 3-deaz ...... -small cell lung cancer cells.

@nl

P1433

Q34296248-C058EFBA-63A5-4F52-AC1E-5B9317FD2788

P1476

Q34296248-84C1549E-3437-4447-8685-D2021195B5DB

P2093

Q34296248-0D0C6A46-318E-4882-8747-29B0AAA61679

Q34296248-19490A6B-7E1E-413D-BF05-A3BE0A3457BF

Q34296248-54CBFC2C-2EA8-470B-81C0-7C3D4E18115E

Q34296248-9C902819-20AE-4D50-A87C-EAF090CC10F3

Q34296248-AA2EE372-3C6B-43A3-B157-DD602155BEC4

Q34296248-C78D98B4-60C7-42DD-8FE5-F5ACC38382A8

Q34296248-F64EA181-9462-418C-8190-C3ED667524E3

Q34296248-F9587EBE-B450-48F0-9D12-DA129648D499

Q34296248-FBCBBC74-B7D5-42D5-866F-68C73E2841B9

P2860

Q34296248-045C415E-E7DF-43D7-9274-FDB0FF22E259

Q34296248-0A3E6E43-7E1E-47C2-91E0-6F2209926510

Q34296248-0CA99961-BB7B-4234-A8AF-62238CB0FB0E

Q34296248-0D7A857B-6676-4C91-A991-CFA1BD6FE3BB

Q34296248-13D42F17-7960-4748-8253-9407D740682E

Q34296248-1BD71F6C-A8EB-4AC8-B371-E5DBE7651F18

Q34296248-1E8F6C28-C967-4E9C-A596-F58C487CBE63

Q34296248-22B9AF13-0C37-4470-820B-8E87BD84BC54

Q34296248-24E1A458-FE9A-425E-8171-F2ED7FB5E9A5

Q34296248-368647EE-AB60-4227-B68A-7CC995E96786

P304

Q34296248-58AA13EC-A205-46D3-8886-EFD029F22053

P31

Q34296248-95DDE779-C349-42EF-80E4-303B9F10FF56

P356

Q34296248-06486783-C86C-4878-BA84-B51DB99913B7

P433

Q34296248-C511F413-F6C0-4578-B0E8-163320392AAA

P478

Q34296248-F10D5F8E-EBF4-43AB-85C7-E5F5A83F42E2

P50

Q34296248-F83CE34C-2481-4F0A-82A0-4168DF29DFD4

P577

Q34296248-937D1A19-2906-447B-9B7E-59F5A81E3D55

P5875

Q34296248-2A0E3BF3-7B7B-4AFA-9DAA-B285AA82E7D8

P698

Q34296248-29172A34-830A-41D3-B49C-97E8B9919FA2

P932

Q34296248-74EC9383-D24B-43EF-A01F-636A59DDD2F0

P356

J.LUNGCAN.2012.08.003

P1433

P1476

Epigenetic therapy with 3-deaz ...... n-small cell lung cancer cells

@en

P2093

Eiki Kikuchi

http://www.w3.org/2001/XMLSchema#string

Hirotoshi Dosaka-Akita

http://www.w3.org/2001/XMLSchema#string

Ichiro Kinoshita

http://www.w3.org/2001/XMLSchema#string

Jun Sakakibara-Konishi

http://www.w3.org/2001/XMLSchema#string

Junko Kikuchi

http://www.w3.org/2001/XMLSchema#string

Satoshi Oizumi

http://www.w3.org/2001/XMLSchema#string

Taichi Takashina

http://www.w3.org/2001/XMLSchema#string

Victor E Marquez

http://www.w3.org/2001/XMLSchema#string

Yasushi Shimizu

http://www.w3.org/2001/XMLSchema#string

P2860

DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Cancer statistics, 2010

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins

The polycomb group protein EZH2 is involved in progression of prostate cancer

Polycomb silencers control cell fate, development and cancer

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines

P304

138-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2012.08.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

Masaharu Nishimura

P577

2012-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230747631

http://www.w3.org/2001/XMLSchema#string

P698

22925699

http://www.w3.org/2001/XMLSchema#string

P932

3472089

http://www.w3.org/2001/XMLSchema#string